Skip to content
Other

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

West Pharmaceutical Services Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation decreased by 327.2% to -$269.9M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 235.7%, from -$80.4M to -$269.9M.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2019
Last reportedQ1 2026Apr 23, 2026
Metric ID: other_cash_cash_equivalents_restricted_cash_and_restrict_8b4577

Historical Data

11 periods
 Q3 '21Q1 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$111.8M-$94.9M-$8M-$90M$102.3M-$252.1M-$155.6M-$80.4M$105.5M$118.8M-$269.9M
QoQ Change-184.9%+91.6%<-999%+213.7%-346.4%+38.3%+48.3%+231.2%+12.6%-327.2%
YoY Change+91.6%<-999%-72.9%+68.1%+167.8%-235.7%
Range-$269.9M$118.8M
CAGR+42.3%
Avg YoY Growth-505.4%
Median YoY Growth-2.4%

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at Other Companies

Frequently Asked Questions

What is West Pharmaceutical Services's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
West Pharmaceutical Services (WST) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of -$269.9M in Q1 2026.
How has West Pharmaceutical Services's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
West Pharmaceutical Services's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation decreased by 235.7% year-over-year, from -$80.4M to -$269.9M.